These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 34973108)

  • 21. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
    Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulovic S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte RJ; Huang B; Costa N; Blake-Haskins JA; Grivas P
    Future Oncol; 2022 Jun; 18(19):2361-2371. PubMed ID: 35416053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.
    Manitz J; Gerhold-Ay A; Kieslich P; Shah P; Mrowiec T; Tyroller K
    Cancer Med; 2024 Jun; 13(12):e7411. PubMed ID: 38924353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma-A Cost-Effectiveness Analysis.
    Lin D; Luo S; Lin S; Zhong L; Zhou W; Gu D; Huang X; Chen Q; Xu X; Weng X
    Clin Genitourin Cancer; 2023 Feb; 21(1):8-15. PubMed ID: 36328903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
    Rodriguez-Vida A; Valderrama BP; Castellano D; Pinto A; Mellado B; Puente J; Climent MA; Domenech M; Vazquez F; Perez-Gracia JL; Bonfill T; Morales-Barrera R; Gonzalez-Billalabeitia E; Garcia-Del-Muro X; Maroto P; Navarro-Gorro N; Juanpere N; Juan O; Bellmunt J
    ESMO Open; 2024 Sep; 9(9):103690. PubMed ID: 39214051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
    Bakaloudi DR; Talukder R; Lin GI; Makrakis D; Diamantopoulos LN; Tripathi N; Agarwal N; Zakopoulou R; Bamias A; Brown JR; Pinato DJ; Korolewicz J; Jindal T; Koshkin VS; Murgić J; Miletić M; Frobe A; Johnson J; Zakharia Y; Drakaki A; Rodriguez-Vida A; Rey-Cárdenas M; Castellano D; Buznego LA; Duran I; Carballeira CC; Barrera RM; Marmorejo D; McKay RR; Stewart T; Gupta S; Ruplin AT; Yu EY; Khaki AR; Grivas P
    Clin Genitourin Cancer; 2023 Oct; 21(5):584-593. PubMed ID: 37414620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.
    Xie Q; Zheng H; Chen Y; Peng X
    Front Public Health; 2022; 10():837854. PubMed ID: 35570929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program.
    Park SH; Shin SJ; Rha SY; Beom SH; Seo HK; Keam B; Kim M; Hong YH; Yoon S; Lee JL
    Front Oncol; 2024; 14():1403120. PubMed ID: 38887229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
    Critchlow S; Bullement A; Crabb S; Jones R; Christoforou K; Amin A; Xiao Y; Kapetanakis V; Benedict Á; Chang J; Kearney M; Eccleston A
    Future Oncol; 2024 Mar; 20(8):459-470. PubMed ID: 37529943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
    Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
    Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
    Bellmunt J; Chang J; Pavilack-Kirker M; Cappelleri JC; Costa N; Esterberg E; Kearney M; Hitchens A; Candrilli SD; Ajmera M
    Clin Genitourin Cancer; 2023 Aug; 21(4):459-466. PubMed ID: 37149458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
    Miyake M; Nishimura N; Oda Y; Miyamoto T; Iida K; Inoue K; Tachibana A; Yoshikawa T; Sakamoto K; Ohnishi M; Maesaka F; Takamatsu N; Mieda K; Ohmori C; Matsubara T; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
    Int J Clin Oncol; 2024 Sep; 29(9):1311-1325. PubMed ID: 38888683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
    Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
    Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
    Strauss J; Deville JL; Sznol M; Ravaud A; Maruzzo M; Pachynski RK; Gourdin TS; Maio M; Dirix L; Schlom J; Donahue RN; Tsai YT; Wang X; Vugmeyster Y; Beier F; Seebeck J; Schroeder A; Chennoufi S; Gulley JL
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37236636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
    Uemura M; Tomita Y; Miyake H; Hatakeyama S; Kanayama HO; Numakura K; Takagi T; Kato T; Eto M; Obara W; Uemura H; Choueiri TK; Motzer RJ; Fujii Y; Kamei Y; Umeyama Y; di Pietro A; Oya M
    Cancer Sci; 2020 Mar; 111(3):907-923. PubMed ID: 31883418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma.
    Banek S; Wenzel M; Lauer B; Le QC; Hoeh B; Koll F; Cano Garcia C; Humke C; Köllermann J; Chun FKH; Kosiba M; Kluth LA
    Urol Int; 2024; 108(4):285-291. PubMed ID: 38447555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.
    Wood LS; Conway D; Lapuente M; Salvador G; Fernandez Gomez S; Carroll Bullock A; Devgan G; Burns KD
    J Infus Nurs; 2022 May-Jun 01; 45(3):142-153. PubMed ID: 35537002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
    Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
    Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
    Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Uemura H; Albiges L; Fujii Y; Umeyama Y; Wang J; Mariani M; Schmidinger M
    ESMO Open; 2022 Apr; 7(2):100450. PubMed ID: 35397432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.